Nicole Welch

Nicole Welch

Auto-generated profile, based on publicly available information

Nicole Welch

Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2023 in Gut and Liver
Verified
Journal Article
Open access
PDF file
MKMichelle Kang Kim
Michelle Kang Kim
CRCarol Rouphael
Carol Rouphael
JMJohn McMichael
John McMichael
NWNicole Welch
Nicole Welch
SDSrinivasan Dasarathy
Srinivasan Dasarathy
Michelle Kang Kim, Carol Rouphael, John McMichael, Nicole Welch, and Srinivasan Dasarathy. Gut and Liver 2024;18:201-8. https://doi.org/10.5009/gnl230272

17 February 2023 in Hepatology
Verified
Journal Article
Open access
XWXiaoqin Wu
Xiaoqin Wu
XFXiude Fan
Xiude Fan
MMMegan R. McMullen
Megan R. McMullen
TMTatsunori Miyata
Tatsunori Miyata
AKAdam Kim
Adam Kim
LNLaura E Nagy
Laura E Nagy
Background and Aims: Mixed lineage kinase domain‐like pseudokinase (MLKL), a key terminal effector of necroptosis, also plays a role in intracellular vesicle trafficking that is critical for regulating liver inflammation and injury in alcohol‐associated liver disease (ALD). Although receptor interacting protein kinase 3 (Rip3) −/− mice are completely protected from ethanol‐induced liver injury, Mlkl −/− mice are only partially protected. Therefore, we hypothesized that cell‐specific functions of MLKL may contribute to ethanol‐induced injury. Approach and Results: Bone marrow transplants between Mlkl −/− mice and littermates were conducted to distinguish the role of myeloid versus nonmyeloid Mlkl in the Gao‐binge model of ALD. Ethanol‐induced hepatic injury, steatosis, and inflammation were exacerbated in Mlkl −/− →wild‐type (WT) mice, whereas Mlkl deficiency in nonmyeloid cells (WT→Mlkl −/− ) had no effect on Gao‐binge ethanol‐induced injury. Importantly, Mlkl deficiency in myeloid cells exacerbated ethanol‐mediated bacterial burden and accumulation of immune cells in livers. Mechanistically, challenging macrophages with lipopolysaccharide (LPS) induced signal transducer and activator of transcription 1–mediated expression and phosphorylation of MLKL, as well as translocation and oligomerization of MLKL to intracellular compartments, including phagosomes and lysosomes but not plasma membrane. Importantly, pharmacological or genetic inhibition of MLKL suppressed the phagocytic capability of primary mouse Kupffer cells (KCs) at baseline and in response to LPS with/without ethanol as well as peripheral monocytes isolated from both healthy controls and patients with alcohol‐associated hepatitis. Further, in vivo studies revealed that KCs of Mlkl −/− mice phagocytosed fewer bioparticles than KCs of WT mice. Conclusion: Together, these data indicate that myeloid MLKL restricts ethanol‐induced liver inflammation and injury by regulating hepatic immune cell homeostasis and macrophage phagocytosis.

1 May 2019 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
Sashi KantSashi Kant
Sashi Kant
GDGangarao Davuluri
Gangarao Davuluri
KAKhaled A. Alchirazi
Khaled A. Alchirazi
NWNicole Welch
Nicole Welch
CHClaire Heit
Claire Heit
SDSrinivasan Dasarathy
Srinivasan Dasarathy
Ethanol causes dysregulated muscle protein homeostasis while simultaneously causing hepatocyte injury. Because hepatocytes are the primary site for physiological disposal of ammonia, a cytotoxic cellular metabolite generated during a number of metabolic processes, we determined whether hyperammonemia aggravates ethanol-induced muscle loss. Differentiated murine C2C12 myotubes, skeletal muscle from pair-fed or ethanol-treated mice, and human patients with alcoholic cirrhosis and healthy controls were used to quantify protein synthesis, mammalian target of rapamycin complex 1 (mTORC1) signaling, and autophagy markers. Alcohol-metabolizing enzyme expression and activity in mouse muscle and myotubes and ureagenesis in hepatocytes were quantified. Expression and regulation of the ammonia transporters, RhBG and RhCG, were quantified by real-time PCR, immunoblots, reporter assays, biotin-tagged promoter pulldown with proteomics, and loss-of-function studies. Alcohol and aldehyde dehydrogenases were expressed and active in myotubes. Ethanol exposure impaired hepatocyte ureagenesis, induced muscle RhBG expression, and elevated muscle ammonia concentrations. Simultaneous ethanol and ammonia treatment impaired protein synthesis and mTORC1 signaling and increased autophagy with a consequent decreased myotube diameter to a greater extent than either treatment alone. Ethanol treatment and withdrawal followed by ammonia exposure resulted in greater impairment in muscle signaling and protein synthesis than ammonia treatment in ethanol-naive myotubes. Of the three transcription factors that were bound to the RhBG promoter in response to ethanol and ammonia, DR1/NC2 indirectly regulated transcription of RhBG during ethanol and ammonia treatment. Direct effects of ethanol were synergistic with increased ammonia uptake in causing dysregulated skeletal muscle proteostasis and signaling perturbations with a more severe sarcopenic phenotype.

22 December 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
AKAvinash Kumar
Avinash Kumar
NWNicole Welch
Nicole Welch
SMSaurabh MISHRA
Saurabh MISHRA
ABAnnette Bellar
Annette Bellar
RSRafaella Nasciemento Silva
Rafaella Nasciemento Silva
SDSrinivasan Dasarathy
Srinivasan Dasarathy
Ammonia is a cytotoxic metabolite with pleiotropic molecular and metabolic effects, including senescence induction. During dysregulated ammonia metabolism, which occurs in chronic diseases, skeletal muscle becomes a major organ for nonhepatocyte ammonia uptake. Muscle ammonia disposal occurs in mitochondria via cataplerosis of critical intermediary metabolite α -ketoglutarate, a senescence-ameliorating molecule. Untargeted and mitochondrially targeted data were analyzed by multiomics approaches. These analyses were validated experimentally to dissect the specific mitochondrial oxidative defects and functional consequences, including senescence. Responses to ammonia lowering in myotubes and in hyperammonemic portacaval anastomosis rat muscle were studied. Whole-cell transcriptomics integrated with whole-cell, mitochondrial, and tissue proteomics showed distinct temporal clusters of responses with enrichment of oxidative dysfunction and senescence-related pathways/proteins during hyperammonemia and after ammonia withdrawal. Functional and metabolic studies showed defects in electron transport chain complexes I, III, and IV; loss of supercomplex assembly; decreased ATP synthesis; increased free radical generation with oxidative modification of proteins/lipids; and senescence-associated molecular phenotype–increased β -galactosidase activity and expression of p16 INK , p21, and p53. These perturbations were partially reversed by ammonia lowering. Dysregulated ammonia metabolism caused reversible mitochondrial dysfunction by transcriptional and translational perturbations in multiple pathways with a distinct skeletal muscle senescence-associated molecular phenotype.

18 February 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
NWNicole Welch
Nicole Welch
AAAmy H. Attaway
Amy H. Attaway
ABAnnette Bellar
Annette Bellar
HAHayder Alkhafaji
Hayder Alkhafaji
AVAdil Vural
Adil Vural
SDSrinivasan Dasarathy
Srinivasan Dasarathy
Background: There are limited data on outcomes of older patients with chronic diseases. Skeletal muscle loss of aging (primary sarcopenia) has been extensively studied but the impact of secondary sarcopenia of chronic disease is not as well evaluated. Older patients with chronic diseases have both primary and secondary sarcopenia that we term compound sarcopenia. We evaluated the clinical impact of compound sarcopenia in hospitalized patients with cirrhosis given the increasing number of patients and high prevalence of sarcopenia in these patients. Design: The Nationwide Inpatients Sample (NIS) database (years 2010–2014) was analyzed to study older patients with cirrhosis. Since there is no universal hospital diagnosis code for “muscle loss”, we used a comprehensive array of codes for “muscle loss phenotype” in the international classification of diseases-9 (ICD-9). A randomly selected 2% sample of hospitalized general medical population (GMP) and inpatients with cirrhosis were stratified into 3 age groups based on age-related changes in muscle mass. In-hospital mortality, length of stay (LoS), cost of hospitalization (CoH), comorbidities and discharge disposition were analyzed. Results. Of 517,605 hospitalizations for GMP and 106,835 hospitalizations for treatment of cirrhosis or a cirrhosis-related complication, 207,266 (40.4%) GMP and 29,018 (27.7%) patients with cirrhosis were >65 years old, respectively. Muscle loss phenotype in both GMP and inpatients with cirrhosis 51–65 years old and >65 years old was significantly (p < 0.001 for all) associated with higher mortality, LoS, and CoH compared to those ≤50 years old. Patients >65 years old with cirrhosis and muscle loss phenotype had higher mortality (adjusted OR: 1.06, 95% CI [1.04, 1.08] and CoH (adjusted odds ratio (OR): 1.10, 95% confidence interval (CI) [1.04, 1.08])) when compared to >65 years old GMP with muscle loss phenotype. Muscle loss in younger patients with cirrhosis (≤50 years old) was associated with worse outcomes compared to GMP >65 years old. Non-home discharges (nursing, skilled, long-term care) were more frequent with increasing age to a greater extent in patients with cirrhosis with muscle loss phenotype for each age stratum. Conclusion: Muscle loss is more frequent in older patients with cirrhosis than younger patients with cirrhosis and older GMP. Younger patients with cirrhosis had clinical outcomes similar to those of older GMP, suggesting an accelerated senescence in cirrhosis. Compound sarcopenia in older patients with cirrhosis is associated with higher inpatient mortality, increased LoS, and CoH compared to GMP with sarcopenia.

1 June 2020 in Journal of Applied Physiology
Verified
Journal Article
Closed access
PDF file
ABAnnette Bellar
Annette Bellar
NWNicole Welch
Nicole Welch
SDSrinivasan Dasarathy
Srinivasan Dasarathy
Reduced exercise capacity and impaired physical performance are observed in nearly all patients with liver cirrhosis. Physical activity and exercise are physiological anabolic stimuli that can reverse dysregulated protein homeostasis or proteostasis and potentially increase muscle mass and contractile function in healthy subjects. Cirrhosis is a state of anabolic resistance, and unlike the beneficial responses to exercise reported in physiological states, there are few systematic studies evaluating the response to exercise in cirrhosis. Hyperammonemia is a mediator of the liver-muscle axis with net skeletal muscle ammonia uptake in cirrhosis causing signaling perturbations, mitochondrial dysfunction with decreased ATP content, modifications of contractile proteins, and impaired ribosomal function, all of which contribute to anabolic resistance in cirrhosis and have the potential to impair the beneficial responses to exercise. English language-publications in peer-reviewed journals that specifically evaluated the impact of exercise in cirrhosis were reviewed. Most studies evaluated responses to endurance exercise, and readouts included peak or maximum oxygen utilization, grip strength, and functional capacity. Endurance exercise for up to 12 wk is clinically tolerated in well-compensated cirrhosis. Data on the safety of resistance exercise are conflicting. Nutritional supplements enhance the benefits of exercise in healthy subjects but have not been evaluated in cirrhosis. Whether the beneficial physiological responses with endurance exercise and increase in muscle mass with resistance exercise that occur in healthy subjects also occur in cirrhotics is not known. Specific organ-system responses, changes in body composition, or improved long-term clinical outcomes with exercise in cirrhosis need evaluation.